NASDAQ: NRXP - NRx Pharmaceuticals, Inc.

Yield per half year: +88.46%
Dividend yield: 0%
Sector: Healthcare

Share chart NRx Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-12-04
ISIN US6294441000
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.nrxpharma.com
Цена ао 2.29
Change price per day: +2.08% (2.4)
Change price per week: +20.1% (2.04)
Change price per month: +26.94% (1.93)
Change price per 3 month: -14.04% (2.85)
Change price per half year: +88.46% (1.3)
Change price per year: -30.79% (3.54)
Change price per 3 year: +85.61% (1.32)
Change price per 5 year: -77.06% (10.68)
Change price per year to date: +72.54% (1.42)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -0.6929 0
P/E 0 0
EV/EBITDA -1.15 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -458.25 0
ROE, % 143.76 10
Total: 3.33

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.3555 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % -64 0
Yield EPS, % 563.05 10
Total: 6
More

Institutions Volume Share, %
Vanguard Group Inc 144518 0.15
AdvisorShares Investments, LLC 64263 0.07
Geode Capital Management, LLC 41192 0.04
Blackrock Inc. 29071 0.03
Renaissance Technologies, LLC 20048 0.02
Royal Bank of Canada 15021 0.02
One Wealth Management Investment & Advisory Services, LLC 14040 0.01
Bridgeway Capital Management, Inc. 12270 0.01
State Street Corporation 11424 0.01
Northern Trust Corporation 7500 0.01



Head Job title Payment Year of birth
Mr. Stephen H. Willard Esq. Acting Corporate Secretary, CEO & Director 500k 1961 (64 years)
Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chief Scientist Officer & Chairman 630.2k 1957 (68 years)
Dr. Riccardo Panicucci Ph.D. Chief Manufacturing & Technology Officer 240k 1961 (64 years)
Mr. Richard Clavano Narido CFO & Treasurer 255.01k 1979 (46 years)
Suzanne Messere Investor Relations N/A
Dr. Philip T. Lavin Ph.D. Chief Methodologist N/A 1947 (78 years)
Mr. Matthew Patrick Duffy Chief Business Officer N/A 1963 (62 years)

Address: United States, Wilmington. DE, 1201 Orange Street - open in Google maps, open in Yandex maps
Website: https://www.nrxpharma.com